 Flexion Therapeutics Inc NASDAQ: FLXN expanded the Phase 1b trial of FX301 in patients undergoing bunionectomy. Related: Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery. 